...
首页> 外文期刊>Journal of gastroenterology >A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.
【24h】

A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.

机译:新型口服抑制DPD的化疗药物S-1和干扰素-α联合化疗成功治疗了多发性肺,脾和肝残留转移的肝细胞癌。

获取原文
获取原文并翻译 | 示例

摘要

A 54-year-old man was admitted Osaka University Hospital for hepatocellular carcinoma (HCC) with portal vein thrombus and multiple intrahepatic metastases that extended to the bilateral lobes of the liver. He underwent multimodal therapy, including extended left lobectomy followed by intra-arterial 5-fluorourcil (5-FU) infusion chemotherapy combined with subcutaneous interferon-alpha (IFN-alpha) to treat the lesions in the residual liver. Seven months after the initial resection, recurrent tumors in the spleen, lung, and residual liver were detected by follow-up examination. We started a new regimen of per oral administration of S-1 and subcutaneous IFN-alpha injection, because the combined therapy with intra-arterial 5-FU infusion was not considered effective for distant metastases. After two cycles of S-1 and IFN-alpha, the metastatic tumor in the spleen and the recurrence in the residual liver had disappeared, and the diagnosis was complete remission with no adverse effect; the pulmonary metastasis showed a partial response, and was finally resected. This patient is still alive with no recurrence 32 months after initial hepatic resection. This outcome suggests that combination therapy with S-1 and IFN-alpha may be a promising treatment modality against advanced HCC with distant metastasis.
机译:一名54岁的男子因肝细胞癌(HCC)进入大阪大学医院,门静脉血栓和多处肝内转移扩展至肝双叶。他接受了多模式治疗,包括扩大左叶切除术,然后进行动脉内5-氟尿嘧啶(5-FU)灌注化疗结合皮下干扰素-α(IFN-α)来治疗残留肝脏中的病变。初次切除七个月后,通过随访检查发现了脾脏,肺脏和残留肝脏中的复发性肿瘤。我们开始了一种口服S-1和皮下注射IFN-α的新方案,因为联合使用动脉内5-FU输注疗法被认为对远处转移无效。经过两个周期的S-1和IFN-α治疗后,脾脏转移瘤和残留肝的复发消失,诊断完全缓解,无不良反应。肺转移显示出部分反应,最后被切除。初次肝切除术后32个月,该患者仍活着且未复发。该结果表明,S-1和IFN-α的联合治疗可能是针对远距离转移的晚期HCC的有前途的治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号